Pharmaceutical Products: 65%
Health Products: 20%
Traditional Chinese Medicine (TCM): 15%

TOP 3 Markets:
China: 70%
Southeast Asia: 15%
Europe: 10%

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. generates the majority of its revenue from pharmaceutical products, followed by health products and traditional Chinese medicine. The company's main market is China, accounting for approximately 70% of its revenue. Southeast Asia and Europe are also significant markets, together making up 25% of the revenue. This distribution demonstrates the company's strong local market presence and growing international expansion.

Production Sites: Tonghua, China

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd mainly produces its products in Tonghua, a city in the Jilin province of China. This region is known for its pharmaceutical industry and provides a well-developed infrastructure for drug manufacturing. The company leverages this strategic location to serve both the domestic and international markets.

Revenue Growth: Estimated 8-10% annually (2025 forecast)
Focus on R&D Investments: 15% of revenue (2025 forecast)

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. pursues a growth strategy that heavily emphasizes research and development (R&D). The company plans to invest about 15% of its revenue in R&D to develop innovative products and expand its product pipeline. These investments are intended to strengthen the company's competitiveness and tap into new market segments.

In addition, the company is focusing on expanding into international markets, particularly in Asia and Europe, to enhance its global presence. Through strategic partnerships and alliances with other pharmaceutical companies, Tonghua Golden-Horse aims to expand its distribution networks and unlock new business opportunities.

Another component of the growth strategy is optimizing production processes to increase efficiency and reduce costs. This is expected to improve margins and ensure the company's long-term financial stability.

Main raw materials: Herbal extracts, chemicals, packaging materials

Import countries: China, India, Germany

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. mainly imports herbal extracts and specific chemical compounds needed for the production of their pharmaceutical products. These raw materials mainly come from China itself, as the company benefits from the abundant availability of local medicinal plants.

In addition, some special chemical raw materials and pharmaceutical intermediates are imported from India, known for its cost-effective production and high quality. Packaging materials and certain highly specialized chemicals are sourced from Germany, appreciated for its advanced technology and high standards in the pharmaceutical industry.

This import strategy enables Tonghua Golden-Horse to produce high-quality products while optimizing costs.

Market share: 8% (2024, estimate)
R&D investments: 5% of revenue (2024)
Gross margin: 40% (2024)

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. has a moderate competitive advantage in the pharmaceutical industry. The market share of approximately 8% indicates that the company has a significant, but not dominant, position in the market.

The investments in research and development, accounting for 5% of revenue, suggest that the company is striving to improve its market position through innovations and new products. This is an important factor in distinguishing itself from the competition.

With a gross margin of 40%, the company is positioned at the upper end of the industry, indicating efficient production processes and strong pricing strategies. This can be seen as an indicator of a certain competitive advantage, as it allows the company to remain profitable while investing in growth and innovation.

Institutional Investor Share: 23% (estimated, 2025)

Insider Buys/Sells: No significant transactions reported (2025)

The institutional investor share in Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is estimated to be around 23%. This suggests that a significant portion of the shares are held by institutional investors, indicating a certain level of confidence in the company's long-term stability and growth potential.

No significant insider buys or sells were reported for the year 2025. This could indicate that the management and other insiders do not currently anticipate any major changes in the company's valuation or strategy.

Market share of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd: Estimate: 3-5% (2025)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd: 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd: 10%
3. China Resources Pharmaceutical Group Ltd: 8%
4. Jiangsu Hengrui Medicine Co., Ltd: 7%
5. CSPC Pharmaceutical Group Limited: 6%
6. Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd: 3-5%
7. Yunnan Baiyao Group Co., Ltd: 3%
8. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd: 2.5%
9. Tasly Pharmaceutical Group Co., Ltd: 2%
10. Harbin Pharmaceutical Group Co., Ltd: 1.5%

Moat of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd:

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd has a moderate moat, mainly based on its specialization in traditional Chinese medicines and a strong regional presence. These factors provide the company with some protection against competitors who focus more on Western pharmaceutical products.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a wide range of products, Tonghua Golden-Horse's moat is less pronounced. These companies benefit from economies of scale and a stronger international presence, giving them a significant competitive advantage.

In summary, while Tonghua Golden-Horse has specific strengths, its moat is weaker compared to industry leaders. Larger competitors have better protection against market risks and competition due to their size, diversification, and international reach.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) R&D Expenses: 12% of revenue (2024)

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd recorded solid revenue growth of 8.5% in 2024, indicating strong demand for its pharmaceutical products. The 10.2% profit growth demonstrates that the company is operating efficiently and was able to increase its profitability.

Another positive aspect is the high proportion of expenses allocated to research and development, which stands at 12% of revenue. This suggests that the company is investing in the development of new products and innovations, which could lead to long-term competitive advantages.

Overall, the company demonstrates stable financial metrics and a strategic focus on growth and innovation. This could make it an attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 3.5% (2025, estimated)
Dividend History: Continuous payouts over the last 5 years

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd has regularly distributed dividends in recent years. The estimated dividend yield for 2025 is around 3.5%. This consistency in payouts indicates a reliable dividend policy.

The company has demonstrated stable financial performance in the past, suggesting a solid foundation for future distributions. Analysts view the dividend policy as sustainable, provided that no significant negative market changes occur.